A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients

• Status: Completed
• Trial end date: 2001-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerance, and overall effectiveness of cidovir to treat PML in AIDS patients.

PML is an opportunistic infection (HIV-associated, due to weak immune system) caused by a virus that attacks the brain. Cidovir has been used effectively to treat cytomegalovirus (CMV) of the eye. Cidovir could be an effective treatment for PML as well.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Cidofovir; Probenecid

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV-positive.

• Have had symptoms of PML for no more than 90 days before study entry, or have had abnormal neurological exams related to PML.

• Have negative tests for bacterial or fungal infections.

• Agree to practice abstinence or use effective methods of birth control during the study.

• Are at least 18 years old.

• Have a life expectancy of at least 6 months.

Exclusion Criteria

You will not be eligible for this study if you:

• Have a history of uveitis.

• Are allergic to sulfa drugs or probenecid.

• Have had active opportunistic infections other than Kaposi's sarcoma within 30 days before study entry.

• Have sickle cell anemia or trait.

• Are pregnant or breast-feeding.